Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASADENA study of prasinezumab in early Parkinson's disease
2017-000087-15Phase 2Active
- Sponsor
- Roche
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Prasinezumab with Placebo (2 arms). Primary endpoint: Change in total MDS-UPDRS score from baseline at Week 52. Started May 2017; status: active.
02
Drugs
prasinezumab
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2017-000087-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000087-15.